Consensus X4 Pharmaceuticals, Inc.

Equities

XFOR

US98420X1037

Market Closed - Nasdaq Other stock markets 21:30:01 03/05/2024 BST			5-day change	1st Jan Change
1.15 ^USD	+6.48%		-1.29%	+37.15%

04-30	HC Wainwright Adjusts Price Target on X4 Pharmaceuticals to $5 From $3, Maintains Buy Rating	MT
04-29	Pantherx® Rare Partner with X4 Pharmaceuticals Inc. for the Distribution of Xolremdi? (Mavorixafor), the First FDApproved Therapy Indicated for Use in Patients with Whim Syndrome	CI

Evolution of the average Target Price on X4 Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

2e24507723ce0ae2151604542866486.Xr5aEKAhcqXQ_b69cr8vR1O998L3Z2IaLwMMqMDvNRQ.Newsfe1NP9CpiO_4G-1tNh6QsabEJQdvSHA66rG6cHE41w4lyGsZ7LGW5w~3133426040bb6808c386a6bb4f6a2cda

Analyst Recommendations on X4 Pharmaceuticals, Inc.

HC Wainwright Adjusts Price Target on X4 Pharmaceuticals to $5 From $3, Maintains Buy Rating	04-30	MT
B. Riley Downgrades X4 Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $1 From $3	12-12	MT
B. Riley Trims X4 Pharmaceuticals' Price Target to $3 From $4, Keeps Buy Rating	30/08/23	MT
B. Riley Lifts X4 Pharmaceuticals' PT to $4 From $3, Notes 'Impressive' Follow-On Phase III WHIM Infections' Data; Keeps Buy Rating	18/05/23	MT
Stifel Adjusts Price Target on X4 Pharmaceuticals to $5 From $4, Maintains Buy Rating	17/05/23	MT
X4 Pharmaceuticals, Inc. Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Time of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome	16/05/23	CI
B. Riley Lowers X4 Pharmaceuticals' Price Target to $3 From $7 In Light of Recent Financing Resulting in Share Increase; Keeps Buy Rating	10/04/23	MT
Oppenheimer Adjusts X4 Pharmaceuticals Price Target to $4 From $5, Maintains Outperform Rating	24/03/23	MT
HC Wainwright Adjusts X4 Pharmaceuticals Price Target to $3 From $5, Maintains Buy Rating	22/03/23	MT
Cantor Fitzgerald Initiates X4 Pharmaceuticals With Overweight Rating, $3 Price Target	22/12/22	MT
Piper Sandler Starts X4 Pharmaceuticals at Overweight With $3 Price Target	12/12/22	MT
H.C. Wainwright Boosts Price Target on X4 Pharmaceuticals to $5 From $3.50, Reiterates Buy Rating	30/11/22	MT
Oppenheimer Adjusts X4 Pharmaceuticals Price Target to $5 From $8, Maintains Outperform Rating	08/08/22	MT
B. Riley Lowers X4 Pharmaceuticals' Price Target to $7 from $10 After Q1 Earnings Came Slightly Below Estimates, Keeps Buy Rating	19/05/22	MT
HC Wainwright Adjusts X4 Pharmaceuticals' Price Target to $8.50 from $11, Keeps Buy Rating	13/05/22	MT
Oppenheimer Adjusts X4 Pharmaceuticals' Price Target to $8 From $13, Maintains Outperform Rating	13/05/22	MT
Canaccord Genuity Adjusts Price Target on X4 Pharmaceuticals to $10 From $20, Reiterates Buy Rating	05/04/22	MT
Oppenheimer Adjusts X4 Pharmaceuticals' Price Target to $13 From $16, Maintains Outperform Rating	21/03/22	MT
B. Riley Lowers X4 Pharmaceuticals' PT to $10 from $15 on Increased Research, Development Spend Near Term, Lowered Drug Pricing; Keeps Buy Rating	16/12/21	MT
HC Wainwright Adjusts X4 Pharmaceuticals' Price Target to $11 From $21, Reiterates Buy Rating	14/12/21	MT
X4 PHARMACEUTICALS : Brookline Capital Starts X4 Pharmaceuticals at Buy With $21 Price Target	17/12/20	MT
X4 PHARMACEUTICALS : Canaccord Genuity Adjusts X4 Pharmaceuticals PT to $20 From $22, Maintains Buy Rating	09/11/20	MT